Legislation formally calls for research into treatment, cure for devastating lung disease
WASHINGTON, Oct. 17 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) announced the passage of important legislation that recognizes the need for research into the cause of idiopathic pulmonary fibrosis (IPF), a deadly lung disease with no known cause, no FDA-approved treatment, or cure and a diseases which claims 40,000 lives a year, the same number as are lost to breast cancer.
House Concurrent Resolution 182 (H. Con. Res. 182) passed by a vote of 414-0. The resolution raises the importance of the urgent need to identify viable treatments and an eventual cure for IPF, a disease that is becoming alarmingly more prevalent in the United States.
"The passage of this legislation is a tremendous benchmark for the IPF community," said Mark Shreve, chief executive officer of the Coalition for Pulmonary Fibrosis. "This effort reaffirms our voice is being heard by Congress. We are especially appreciative of Members of Congress for their support, particularly U.S. Rep. Nathan Deal (R-GA) for introducing the resolution and Rep. Brian Baird (D-WA) and Rep. Mike Castle (R-DE) for their co-sponsorship. We are also grateful to the late Rep. Charlie Norwood and his family for their efforts to help raise awareness of IPF."
In speeches on the House floor, Rep. Baird (D-WA) said, "I want to commend families and friends from the Coalition for Pulmonary Fibrosis who were here a couple of weeks ago on Capitol Hill lobbying in support of this legislation...We would hope that this is a first step. Our hope is that by increasing the awareness of our colleagues here in Congress and of the American public that we can not only increase awareness of the disease but begin work towards actual dedicated funding for this."
Rep. Vito Fossella (R-NY) said, "The purpose of this resolution is to
bring awareness to the severity of this devastating
|SOURCE Coalition for Pulmonary Fibrosis|
Copyright©2007 PR Newswire.
All rights reserved